Kiniksa Pharmaceuticals, Ltd.
KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatoā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$48.43
Price+0.10%
$0.05
1Y
Price
Market Cap
$3.641b
Mid
Price/Earnings 3y Avg5y Avg
53.2x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+13.9%
EBITDA Margin+10.5%
Net Profit Margin+23.4%
Free Cash Flow Margin+13.9%
EBITDA Margin+10.5%
Net Profit Margin+23.4%
Free Cash Flow MarginRevenue
$754.045m
+11.3%
1y CAGR+42.7%
3y CAGR+37.7%
5y CAGREarnings
$73.058m
+23.8%
1y CAGR-48.7%
3y CAGR-59.6%
5y CAGREPS
$0.91
+21.3%
1y CAGR-51.2%
3y CAGR-61.5%
5y CAGRBook Value
$605.687m
$825.280m
Assets$219.593m
Liabilities$9.025m
DebtDebt to Assets
1.1%
0.1x
Debt to EBITDAFree Cash Flow
$164.230m
+546.3%
1y CAGR+213.1%
3y CAGR+192.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company